Seres Therapeutics Inc. plans to start selling its first FDA-approved product, a drug called Vowst made of bacterial spores derived from donated feces, this summer at $17,500 a course.

Seres Therapeutics (MCRB) announced new translational biomarker results for exploratory endpoints from its SER-155 Phase 1b placebo-controlled study in patients undergoing allogenic stem cell ...

SERES introduced the new products SERES 5 MAX and SERES 7, to the Latin American region. SERES 5 and DFSK E5, as star products, have already been exported to many countries and regions, receiving ...

CAMBRIDGE, Mass., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) (Seres or the Company), a leading live biotherapeutics company, announced today the receipt of a $50 ...

RAIL, a Pakistani conglomerate, partnered with Seres, a global provider of electric vehicles, in 2021. This partnership brought forth the vision to manufacture and market Seres vehicles in Pakistan.